Study Confirms Safety and Efficacy of Houtou Jianweiling Tablet for Chronic Non-atrophic Gastritis

Background: Chronic Non-atrophic Gastritis (CNAG) is characterized by symptoms such as nausea, stomach distension, and abdominal pain. The Houtou Jianweiling Tablet (HTJWT) has been used clinically for over 20 years, showing proven efficacy in treating CNAG. This study aimed to establish the clinical efficacy and safety of HTJWT in the Pakistani population.

Methods: Conducted between November 2022 and February 2023, the trial involved 240 CNAG patients randomly assigned to either the HTJWT treatment group or the Omeprazole control group. Patients in the treatment group received HTJWT tablets, while the control group received Omeprazole. The study duration was 28 days, with safety evaluations including adverse events, laboratory tests, and vital signs monitoring.

Results: The clinical improvement rate was 91.1% in the treatment group and 91.0% in the control group, indicating negligible variation. The negative conversion rate of Helicobacter pylori was similar between groups. No significant differences were observed in vital signs, laboratory results, or ECG assessments. The control group showed a faster remission period for gastrointestinal discomfort. Only one patient in the control group experienced mild to moderate adverse events.

Conclusion: The study concluded that HTJWT is non-inferior to Omeprazole for treating CNAG, with no significant adverse events reported. The findings support the safety and efficacy of HTJWT as a treatment option for CNAG patients with mild to moderate symptoms.